Tarsus Pharmaceuticals TARS Cash Flow Statement (2019-2026)

NASDAQ TARS
$71.03 +1.53 (+2.20%)
At close: Oct 20, 2026 · 4:00 PM EDT
Reported Financials

Tarsus Pharmaceuticals Quarterly Cash Flow Statement

Periods 28 quarters
Latest Jun 2026

Tarsus Pharmaceuticals reported cash from operations of $61.22M and free cash flow of $57.15M for the quarter ended Jun 2026, up 308.3% year over year. This cash flow statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-15.70M-14.85M-20.24M-5.74M-22.51M-13.60M-23.42M-31.42M-39.15M-41.90M-35.73M-33.29M-23.42M-23.11M-25.12M-20.34M-12.59M-8.37M-6.97M-18.55M
Depreciation and DepletionDep. & Depletion
0.10M0.10M0.10M0.10M0.10M0.10M0.20M0.20M0.24M0.20M0.10M0.20M0.20M0.22M0.20M0.20M0.20M0.20M0.80M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.10M0.10M0.10M0.10M0.24M0.24M0.20M0.20M0.28M0.24M0.20M
Amortization of Deferred ChargesAmort. Deferred Charges
0.06M0.04M0.05M0.08M0.08M0.03M0.03M0.11M0.11M0.10M0.13M0.14M0.14M0.15M0.15M0.16M0.16M0.17M
Depreciation & Amortization (CF)Dep. & Amort.
0.08M0.04M0.04M0.09M0.09M0.10M0.10M0.18M0.20M0.24M0.20M0.10M0.20M0.20M0.22M0.20M0.20M0.20M0.20M0.80M
Share-based CompensationStock Comp.
0.78M2.18M2.67M3.53M3.58M3.67M3.91M5.19M5.25M5.48M5.52M7.48M7.42M7.40M6.93M8.23M12.24M14.31M11.97M13.29M
Gains from Sales and DivestituresGains Divest
Gains from Investment SecuritiesGains Investment
-0.35M0.24M-0.25M-0.26M-0.02M0.02M-0.07M0.02M-0.11M0.42M-0.59M-0.01M2.81M
Other non-cash itemsOther Non-Cash
0.10M0.12M0.11M0.11M0.12M0.12M0.17M0.13M0.13M1.94M0.17M0.16M0.14M0.08M0.08M
Change in Working Capital
Change in ReceivablesChange Receivables
-20.00M0.02M-0.02M2.50M-2.50M5.36M11.26M13.26M-0.36M-0.37M17.60M15.67M-4.09M14.29M12.44M30.29M-19.32M
Change in InventoryChange Inventory
0.02M3.09M0.93M0.69M0.65M-0.23M0.08M1.17M-0.04M0.54M0.20M-0.20M
Change in Accured ExpensesChange Accured Exp.
-1.10M0.36M1.97M-2.10M1.43M1.43M-1.31M0.68M5.81M3.53M12.34M7.09M5.87M12.50M10.17M3.17M24.11M7.94M15.46M13.30M
Change in Other Operating AssetsOther Assets Change
-0.45M0.84M-0.72M1.55M2.59M1.00M-3.46M0.87M1.66M2.06M-0.79M-1.42M0.96M7.90M-8.42M23.25M-7.80M-7.47M12.91M-16.76M
Change in Other Operating LiabilitiesOther Liabilities Change
0.04M-0.04M-0.04M-0.03M0.00M0.01M-0.01M-0.03M0.03M0.19M-0.23M0.00M
Other Working Capital ChangesOther WC Changes
0.49M-0.87M0.67M-1.58M-2.59M-0.99M3.45M-0.89M-1.62M-1.87M0.56M1.41M-0.96M-7.90M8.42M-23.25M7.80M7.47M-12.91M16.76M
Cash from OperationsCash from Ops.
7.11M-12.12M-15.29M-4.26M-18.61M-10.87M-21.97M-23.83M-32.36M-39.34M-37.79M-14.40M-8.65M-22.18M-20.65M-29.39M18.26M19.33M-24.65M61.22M
Investing Activities
Capital ExpendituresCapex
0.12M0.27M0.16M0.12M0.10M0.13M0.34M0.79M0.38M0.17M1.04M0.28M0.07M0.59M1.00M1.91M6.36M5.82M4.07M
Change in Property, Plant and EquipmentChange in PP&E
-0.12M-0.27M-0.16M-0.12M-0.10M-0.13M-0.34M-0.79M-0.38M-0.17M-1.04M-0.28M-0.07M-0.59M-1.00M-1.91M-6.36M-5.82M-4.07M
Change in IntangiblesChange Intangibless
5.00M
Purchase of InvestmentsInvestments Purchased
57.03M92.41M28.67M0.00M104.55M47.03M21.09M89.97M125.57M129.70M102.33M36.45M126.80M2.40M
Sale and Maturity of InvestmentsInvestments Sold
40.30M64.88M51.74M2.50M10.54M24.50M35.47M91.22M79.00M99.50M92.08M74.06M44.35M
Cash from Investing ActivitiesCash from Investing
-0.12M-0.27M-0.16M-0.12M-57.13M-87.22M11.29M64.09M47.37M17.85M-102.22M-40.53M3.13M-59.57M-34.94M-51.70M-4.74M49.27M-58.56M37.88M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
20.00M5.00M5.00M75.00M
Non-Current Debt
20.00M5.00M5.00M75.00M
Net Debt Issuances and RepaymentsNet Debt Issuance
20.00M5.00M5.00M75.00M
Change in Capital Stock
Common Stock IssuedStock Issued
0.08M0.23M74.81M-0.14M-74.09M0.01M0.51M99.89M-98.84M108.77M2.68M0.68M-95.36M136.56M1.95M2.56M-132.46M1.20M3.30M
Net Shares Issued and RepurchasedNet Shares Issued
0.08M0.23M74.81M-0.14M-74.09M0.01M0.51M99.89M-98.84M108.77M2.68M0.68M-95.36M136.56M1.95M2.56M-132.46M1.20M3.30M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.08M0.23M74.81M-0.14M-74.09M0.01M0.51M99.89M-98.84M108.77M2.68M0.68M-95.36M136.56M1.95M2.56M-132.46M1.20M3.30M
Other financing activitiesOther financing
-0.30M-0.88M-0.08M-0.04M
Cash from Financing ActivitiesCash from Financing
0.08M-0.07M19.13M74.73M-0.14M0.26M5.01M0.51M104.89M19.76M108.77M42.32M0.64M2.93M136.56M1.95M2.56M2.31M1.20M3.30M
Additional items
Change in Cash
7.07M-12.47M3.68M70.35M-75.87M-97.83M-5.66M40.78M119.90M-1.73M-31.24M-12.61M-4.89M-78.83M80.97M-79.14M16.08M70.92M-82.01M102.40M
Ending Cash Balance
183.80M171.33M175.01M245.36M169.49M71.66M66.00M106.77M226.67M224.95M193.71M181.10M176.21M97.38M178.35M99.21M115.29M186.20M104.19M206.60M
Free Cash FlowFCF
6.99M-12.40M-15.45M-4.38M-18.71M-11.00M-22.31M-24.61M-32.74M-39.34M-37.96M-15.44M-8.93M-22.25M-21.24M-30.39M16.35M12.97M-30.47M57.15M
Net Cash FlowNCF
7.07M-12.47M3.68M70.35M-75.87M-97.83M-5.66M40.78M119.90M-1.73M-31.24M-12.61M-4.89M-78.83M80.97M-79.14M16.08M70.92M-82.01M102.40M
Interest Paid
0.13M0.97M0.58M0.59M0.71M0.73M0.85M0.87M0.47M4.15M2.17M2.07M2.09M2.12M2.06M1.97M1.99M
Income Taxes PaidTaxes Paid
1.93M2.84M

Tarsus Pharmaceuticals Cash Flow Statement API

Pull Tarsus Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=TARS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY